Page last updated: 2024-09-04

tipifarnib and tyrosine

tipifarnib has been researched along with tyrosine in 2 studies

Compound Research Comparison

Studies (tipifarnib)	Trials (tipifarnib)	Recent Studies (post-2010) (tipifarnib)	Studies (tyrosine)	Trials (tyrosine)	Recent Studies (post-2010) (tyrosine)
309	92	94	44,273	846	8,225

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Choudary, A; Freeman, JW; Venkatasubbarao, K	1
Benchitrit, J; Drüeke, TB; Edelman, A; Galmiche, A; Guerrera, IC; Guillonneau, F; Ivanovski, O; Joki, N; Lacour, B; Lucas, A; Maizel, J; Marçon, F; Massy, ZA; Nguyen-Khoa, T; Nikolov, IG; Phan, O	1

Other Studies

2 other study(ies) available for tipifarnib and tyrosine

Article	Year
Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases. Cancer research, 2005, Apr-01, Volume: 65, Issue:7 Topics: Adenocarcinoma; Alkyl and Aryl Transferases; Cell Cycle Proteins; Cell Growth Processes; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Humans; Interleukin-6; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-myc; Quinolones; Serine; STAT3 Transcription Factor; Trans-Activators; Tyrosine; Up-Regulation	2005
Farnesyltransferase inhibitor R115777 protects against vascular disease in uremic mice. Atherosclerosis, 2013, Volume: 229, Issue:1 Topics: Animals; Aorta; Apolipoproteins E; Apoptosis; Atherosclerosis; Blood Proteins; Body Weight; Collagen Type I; Enzyme Inhibitors; Farnesyltranstransferase; Female; Kidney Failure, Chronic; Liver; Macrophages; Mevalonic Acid; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Prenylation; Quinolones; Random Allocation; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tyrosine; Uremia; Vascular Calcification	2013

Article

Year

Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases.

Cancer research, 2005, Apr-01, Volume: 65, Issue:7

Topics: Adenocarcinoma; Alkyl and Aryl Transferases; Cell Cycle Proteins; Cell Growth Processes; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Humans; Interleukin-6; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-myc; Quinolones; Serine; STAT3 Transcription Factor; Trans-Activators; Tyrosine; Up-Regulation

2005

Farnesyltransferase inhibitor R115777 protects against vascular disease in uremic mice.

Atherosclerosis, 2013, Volume: 229, Issue:1

Topics: Animals; Aorta; Apolipoproteins E; Apoptosis; Atherosclerosis; Blood Proteins; Body Weight; Collagen Type I; Enzyme Inhibitors; Farnesyltranstransferase; Female; Kidney Failure, Chronic; Liver; Macrophages; Mevalonic Acid; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Prenylation; Quinolones; Random Allocation; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tyrosine; Uremia; Vascular Calcification

2013